EANS-Adhoc: Intercell obtains results from its first Phase I investigational vaccine study for Streptococcus pneumoniae

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

11.02.2010

» Initial results from a first-in-man Phase I study indicate safety
and immunogenicity of the Streptococcus pneumoniae vaccine candidate

Vienna (Austria), February 11, 2010 - Intercell AG (VSE: "ICLL") today announced
results from a Phase I clinical trial investigating the company's vaccine
candidate for the prevention of infections by the bacterium Streptococcus
pneumoniae. Intercell's investigational prophylactic vaccine candidate (IC47) is
a recombinant subunit vaccine consisting of three highly conserved proteins of
Streptococcus pneumoniae.

In the first-in-man trial, 32 healthy adults were vaccinated with Intercell's
investigational vaccine. Two antigen dosages, with and without addition of
aluminum hydroxide, were applied in four different study groups.

The initial analysis of the data has indicated a good safety and tolerability of
the vaccine candidate, which was confirmed by a Data Safety Monitoring Board.
The vaccine was immunogenic, and antigen dose-dependent induction of antibodies
was confirmed for all three proteins of the vaccine.

"We are pleased that we have been able to generate first-in-man data for a
further vaccine candidate based on antigens discovered through our Antigen
Identification Program (AIP®). Subject to clearance with the authorities and our
partners, we next intend to initiate clinical development in two target
populations - children and the elderly," stated Thomas Lingelbach, Intercell's
Chief Operating Officer.

About Streptococcus pneumoniae infections

Streptococcus pneumoniae, or Pneumococcus, is a very common bacterial infection
in both industrialized and developing countries. In particular, young children
and the elderly represent high-risk populations for developing pneumococcal
infections. Annually, according to the World Health Organization, the bacterium
kills up to one million children under the age of five years worldwide. It
accounts for many bacterial Meningitis cases in adults, is the most common cause
of Pneumonia, and also causes Bacteremia, Meningitis, and Otitis media in young
children.

About Intercell's Streptococcus pneumoniae vaccine

The Company´s vaccine candidate is a recombinant subunit vaccine consisting of
three conserved surface proteins from Streptococcus pneumoniae. Two of these
proteins were discovered using Intercell's proprietary Antigen Identification
Program (AIP®), while the third was in-licensed from the U.S. Centers for
Disease Control and Prevention (CDC).
The development of Intercell's vaccine to prevent pneumococcal disease is
supported by PATH, an international global health non-profit organization.

Further inquiry note:
Intercell AG
Lucia Malfent
Head of Corporate Communications
Tel. +43 1 20620-1303
[email protected]
end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer:   Intercell AG
          Campus Vienna Biocenter  3
          A-1030 Wien 
phone:    +43 1 20620-0
FAX:      +43 1 20620-800
mail:     [email protected] 
WWW:      www.intercell.com
sector:   Biotechnology
ISIN:     AT0000612601
indexes:  ATX Prime, ATX

stockmarkets: official market: Wien
language: English

Digitale Pressemappe: http://www.ots.at/pressemappe/116

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB

print